NCT06433531

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Efficacy of TQH2929 in Healthy Adult Subjects and Psoriasis Subjects

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, single-group, open-label study to evaluate the safety and tolerability of TQH2929 injection at a dose of 900mg in adult subjects with active Generalized Pustular Psoriasis (GPP), and to preliminarily evaluate the efficacy.

Conditions

• Generalized Pustular Psoriasis

Interventions

Type	Name	Description
DRUG	TQH2929 Injection	TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Timeline

• Start date: 2024-06-19
• Primary completion: 2025-07-08
• Completion: 2025-12-01
• First posted: 2024-05-29
• Last updated: 2025-07-30

Locations

7 sites across 1 country: China